PortalPublikationenThe prognostic impact of circulating tumor cells in subtypes...

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

Standard

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. / Wallwiener, Markus; Hartkopf, Andreas Daniel; Baccelli, Irène; Riethdorf, Sabine; Schott, Sarah; Pantel, Klaus; Marmé, Frederik; Sohn, Christof; Trumpp, Andreas; Rack, Brigitte; Aktas, Bahriye; Solomayer, Erich-Franz; Müller, Volkmar; Janni, Wolfgang; Schneeweiss, Andreas; Fehm, Tanja Natascha.

in: BREAST CANCER RES TR, Jahrgang 137, Nr. 2, 2, 2013, S. 503-510.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wallwiener, M, Hartkopf, AD, Baccelli, I, Riethdorf, S, Schott, S, Pantel, K, Marmé, F, Sohn, C, Trumpp, A, Rack, B, Aktas, B, Solomayer, E-F, Müller, V, Janni, W, Schneeweiss, A & Fehm, TN 2013, 'The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.', BREAST CANCER RES TR, Jg. 137, Nr. 2, 2, S. 503-510. <http://www.ncbi.nlm.nih.gov/pubmed/23271327?dopt=Citation>

APA

Wallwiener, M., Hartkopf, A. D., Baccelli, I., Riethdorf, S., Schott, S., Pantel, K., Marmé, F., Sohn, C., Trumpp, A., Rack, B., Aktas, B., Solomayer, E-F., Müller, V., Janni, W., Schneeweiss, A., & Fehm, T. N. (2013). The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. BREAST CANCER RES TR, 137(2), 503-510. [2]. http://www.ncbi.nlm.nih.gov/pubmed/23271327?dopt=Citation

Vancouver

Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. BREAST CANCER RES TR. 2013;137(2):503-510. 2.

Bibtex

@article{5854f99d332f4680bb614ce7704fecd2,
title = "The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.",
abstract = "The detection of circulating tumor cells (CTCs) in the peripheral blood of metastatic breast cancer (MBC) patients is an independent marker of prognosis. This large prospective multicenter study aimed to assess the impact of CTCs on overall survival (OS) and progression free survival (PFS) in patients with predefined molecular subgroups of MBC. To this end, 468 MBC patients were divided into three subgroups based on immunohistochemical staining of the primary tumor: (1) hormone receptor-positive/HER2-negative (HorR+/HER2-), (2) HER2-positive (HER2+), and (3) HorR-negative/HER2-negative (HorR-/HER2-) patients. CTC status (",
keywords = "Humans, Female, Middle Aged, Multivariate Analysis, Prospective Studies, Prognosis, Disease-Free Survival, Tumor Markers, Biological/*blood, Receptor, erbB-2/metabolism, Antineoplastic Agents/therapeutic use, Receptors, Progesterone/metabolism, Antibodies, Monoclonal, Humanized/therapeutic use, Receptors, Estrogen/metabolism, *Neoplastic Cells, Circulating, Breast Neoplasms/*mortality/*pathology/therapy, Humans, Female, Middle Aged, Multivariate Analysis, Prospective Studies, Prognosis, Disease-Free Survival, Tumor Markers, Biological/*blood, Receptor, erbB-2/metabolism, Antineoplastic Agents/therapeutic use, Receptors, Progesterone/metabolism, Antibodies, Monoclonal, Humanized/therapeutic use, Receptors, Estrogen/metabolism, *Neoplastic Cells, Circulating, Breast Neoplasms/*mortality/*pathology/therapy",
author = "Markus Wallwiener and Hartkopf, {Andreas Daniel} and Ir{\`e}ne Baccelli and Sabine Riethdorf and Sarah Schott and Klaus Pantel and Frederik Marm{\'e} and Christof Sohn and Andreas Trumpp and Brigitte Rack and Bahriye Aktas and Erich-Franz Solomayer and Volkmar M{\"u}ller and Wolfgang Janni and Andreas Schneeweiss and Fehm, {Tanja Natascha}",
year = "2013",
language = "English",
volume = "137",
pages = "503--510",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

AU - Wallwiener, Markus

AU - Hartkopf, Andreas Daniel

AU - Baccelli, Irène

AU - Riethdorf, Sabine

AU - Schott, Sarah

AU - Pantel, Klaus

AU - Marmé, Frederik

AU - Sohn, Christof

AU - Trumpp, Andreas

AU - Rack, Brigitte

AU - Aktas, Bahriye

AU - Solomayer, Erich-Franz

AU - Müller, Volkmar

AU - Janni, Wolfgang

AU - Schneeweiss, Andreas

AU - Fehm, Tanja Natascha

PY - 2013

Y1 - 2013

N2 - The detection of circulating tumor cells (CTCs) in the peripheral blood of metastatic breast cancer (MBC) patients is an independent marker of prognosis. This large prospective multicenter study aimed to assess the impact of CTCs on overall survival (OS) and progression free survival (PFS) in patients with predefined molecular subgroups of MBC. To this end, 468 MBC patients were divided into three subgroups based on immunohistochemical staining of the primary tumor: (1) hormone receptor-positive/HER2-negative (HorR+/HER2-), (2) HER2-positive (HER2+), and (3) HorR-negative/HER2-negative (HorR-/HER2-) patients. CTC status (

AB - The detection of circulating tumor cells (CTCs) in the peripheral blood of metastatic breast cancer (MBC) patients is an independent marker of prognosis. This large prospective multicenter study aimed to assess the impact of CTCs on overall survival (OS) and progression free survival (PFS) in patients with predefined molecular subgroups of MBC. To this end, 468 MBC patients were divided into three subgroups based on immunohistochemical staining of the primary tumor: (1) hormone receptor-positive/HER2-negative (HorR+/HER2-), (2) HER2-positive (HER2+), and (3) HorR-negative/HER2-negative (HorR-/HER2-) patients. CTC status (

KW - Humans

KW - Female

KW - Middle Aged

KW - Multivariate Analysis

KW - Prospective Studies

KW - Prognosis

KW - Disease-Free Survival

KW - Tumor Markers, Biological/blood

KW - Receptor, erbB-2/metabolism

KW - Antineoplastic Agents/therapeutic use

KW - Receptors, Progesterone/metabolism

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Receptors, Estrogen/metabolism

KW - Neoplastic Cells, Circulating

KW - Breast Neoplasms/mortality/pathology/therapy

KW - Humans

KW - Female

KW - Middle Aged

KW - Multivariate Analysis

KW - Prospective Studies

KW - Prognosis

KW - Disease-Free Survival

KW - Tumor Markers, Biological/blood

KW - Receptor, erbB-2/metabolism

KW - Antineoplastic Agents/therapeutic use

KW - Receptors, Progesterone/metabolism

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Receptors, Estrogen/metabolism

KW - Neoplastic Cells, Circulating

KW - Breast Neoplasms/mortality/pathology/therapy

M3 - SCORING: Journal article

VL - 137

SP - 503

EP - 510

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 2

M1 - 2

ER -